Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $29.30, demonstrating a -1.64% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.2%. On the other hand, the Dow registered a gain of 0.04%, and the technology-centric Nasdaq increased by 0.04%.
The company's shares have seen an increase of 3.87% over the last month, surpassing the Medical sector's loss of 1.75% and the S&P 500's loss of 0.35%.
The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. The company's upcoming EPS is projected at $0.07, signifying a 16.67% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $893.37 million, reflecting a 49.15% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.79 per share and revenue of $3.22 billion, indicating changes of -249.06% and +37.03%, respectively, compared to the previous year.
Investors should also note any recent changes to analyst estimates for Hims & Hers Health, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 55% decrease. Right now, Hims & Hers Health, Inc. possesses a Zacks Rank of #3 (Hold).
The Medical Info Systems industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HIMS in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hims & Hers Health, Inc. (HIMS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).